Advertisement

Molecular Neurobiology

, Volume 56, Issue 1, pp 141–156 | Cite as

Major Differences in Neurooxidative and Neuronitrosative Stress Pathways Between Major Depressive Disorder and Types I and II Bipolar Disorder

  • Michael MaesEmail author
  • Kamila Landucci Bonifacio
  • Nayara Rampazzo Morelli
  • Heber Odebrecht Vargas
  • Décio Sabbatini Barbosa
  • André F. Carvalho
  • Sandra Odebrecht Vargas Nunes
Article

Abstract

Accumulating evidence indicates that oxidative and nitrosative stress (O&NS) pathways play a key role in the pathophysiology of bipolar disorder (BD) and major depressive disorder (MDD). However, only a handful of studies have directly compared alterations in O&NS pathways among patients with MDD and BD types I (BPI) and BPII. Thus, the current study compared superoxide dismutase (SOD1), lipid hydroperoxides (LOOH), catalase, nitric oxide metabolites (NOx), malondialdehyde (MDA), and advanced oxidation protein products (AOPP) between mood disorder patients in a clinically remitted state. To this end 45, 23, and 37 participants with BPI, BPII, and MDD, respectively, as well as 54 healthy controls (HCs) were recruited. Z-unit weighted composite scores were computed as indices of reactive oxygen species (ROS) production and nitro-oxidative stress driving lipid or protein oxidation. SOD1, NOx, and MDA were significantly higher in MDD than in the other three groups. AOPP was significantly higher in BPI than in HCs and BPII patients. BPII patients showed lower SOD1 compared to all other groups. Furthermore, MDD was characterized by increased indices of ROS and lipid hydroperoxide production compared to BPI and BPII groups. Indices of nitro-oxidative stress coupled with aldehyde production or protein oxidation were significantly different among the three patient groups (BDII > BDI > MDD). Finally, depressive symptom scores were significantly associated with higher LOOH and AOPP levels. In conclusion, depression is accompanied by increased ROS production, which is insufficiently dampened by catalase activity, thereby increasing nitro-oxidative damage to lipids and aldehyde production. Increased protein oxidation with formation of AOPP appeared to be hallmark of MDD and BPI. In addition, patients with BPII may have protection against the damaging effects of ROS including lipid peroxidation and aldehyde formation. This study suggests that biomarkers related to O&NS could aid in the differentiation of MDD, BPI, and BPII.

Keywords

Depression Bipolar disorder Oxidative and nitrosative stress Immune Inflammation 

Notes

Acknowledgements

The authors wish to thank the Centre of Approach and Treatment for Smokers, Psychiatric Unit at UEL, Clinical Laboratory of the University Hospital and Laboratory of Research and Graduate College Hospital (LPG), Brazil.

Author Contributions

All authors contributed to the writing up of the paper. The work was designed by SOVN, MM, DSB, and HOV. Data were collected by SOVN and HOV. Laboratory analyses were conducted by KLB, NRM, and DSB. Statistics were performed by MM. AFC revised the manuscript and provided relevant intellectual content. All authors revised and approved the final draft.

Funding

This study was supported by Health Sciences Postgraduate Program at Londrina State University, Parana, Brazil (UEL), and Ministry for Science and Technology of Brazil (CNPq). CNPq number 470344/2013-0 and CNPq number 465928/2014-5. MM is supported by a CNPq - PVE fellowship and the Health Sciences Graduate Program fellowship, State University of Londrina.

References

  1. 1.
    Maes M (1993) A review on the acute phase response in major depression. Rev Neurosci 4(4):407–416Google Scholar
  2. 2.
    Maes M (2008) The cytokine hypothesis of depression: inflammation, oxidative & nitrosative stress (IO&NS) and leaky gut as new targets for adjunctive treatments in depression. Neuro Endocrinol Lett 29(3):287–291Google Scholar
  3. 3.
    Maes M, Galecki P, Chang YS, Berk M (2011) A review on the oxidative and nitrosative stress (O&NS) pathways in major depression and their possible contribution to the (neuro)degenerative processes in that illness. Prog Neuro-Psychopharmacol Biol Psychiatry 35(3):676–692Google Scholar
  4. 4.
    Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS et al (2011) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35(3):804–817Google Scholar
  5. 5.
    Moylan S, Berk M, Dean OM, Samuni Y, Williams LJ, O'Neil A, Hayley AC, Pasco JA et al (2014) Oxidative & nitrosative stress in depression: why so much stress? Neurosci Biobehav Rev 45:46–62Google Scholar
  6. 6.
    Köhler CA, Freitas TH, Maes M, de Andrade NQ, Liu CS, Fernandes BS, Stubbs B, Solmi M et al (2017) Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies. Acta Psychiatr Scand 135(5):373–387Google Scholar
  7. 7.
    Köhler CA, Freitas TH, Stubbs B, Maes M, Solmi M, Veronese N, de Andrade NQ, Morris G et al (2017) Peripheral alterations in cytokine and chemokine levels after antidepressant drug treatment for major depressive disorder: systematic review and meta-analysis. Mol Neurobiol.  https://doi.org/10.1007/s12035-017-0632-1 Review
  8. 8.
    Sowa-Kućma M, Styczeń K, Siwek M, Misztak P, Nowak RJ, Dudek D, Rybakowski JK, Nowak G et al (2018) Are there differences in lipid peroxidation and immune biomarkers between major depression and bipolar disorder: Effects of melancholia, atypical depression, severity of illness, episode number, suicidal ideation and prior suicide attempts. Prog Neuro-Psychopharmacol Biol Psychiatry 81:372–383Google Scholar
  9. 9.
    Maes M, Delanghe J, Meltzer HY, Scharpé S, D'Hondt P, Cosyns P (1994) Lower degree of esterification of serum cholesterol in depression: relevance for depression and suicide research. Acta Psychiatr Scand 90(4):252–258Google Scholar
  10. 10.
    Maes M, Smith R, Christophe A, Vandoolaeghe E, Van Gastel A, Neels H, Demedts P, Wauters A et al (1997) Lower serum high-density lipoprotein cholesterol (HDL-C) in major depression and in depressed men with serious suicidal attempts: relationship with immune-inflammatory markers. Acta Psychiatr Scand 95(3):212–221PubMedPubMedCentralGoogle Scholar
  11. 11.
    Maes M, De Vos N, Pioli R, Demedts P, Wauters A, Neels H, Christophe A (2000) Lower serum vitamin E concentrations in major depression. Another marker of lowered antioxidant defenses in that illness. J Affect Disord 58(3):241–246PubMedPubMedCentralGoogle Scholar
  12. 12.
    Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2009) Lower plasma coenzyme Q10 in depression: a marker for treatment resistance and chronic fatigue in depression and a risk factor to cardiovascular disorder in that illness. Neuro Endocrinol Lett 30(4):462–469PubMedPubMedCentralGoogle Scholar
  13. 13.
    Sobczak S, Honig A, Christophe A, Maes M, Helsdingen RW, De Vriese SA, Riedel WJ (2004) Lower high-density lipoprotein cholesterol and increased omega-6 polyunsaturated fatty acids in first-degree relatives of bipolar patients. Psychol Med 34(1):103–112PubMedPubMedCentralGoogle Scholar
  14. 14.
    Tsuboi H, Tatsumi A, Yamamoto K, Kobayashi F, Shimoi K, Kinae N (2006) Possible connections among job stress, depressive symptoms, lipid modulation and antioxidants. J Affect Disord 91(1):63–70PubMedPubMedCentralGoogle Scholar
  15. 15.
    Bortolasci CC, Vargas HO, Souza-Nogueira A, Barbosa DS, Moreira EG, Nunes SO, Berk M, Dodd S et al (2014) Lowered plasma paraoxonase (PON)1 activity is a trait marker of major depression and PON1 Q192R gene polymorphism-smoking interactions differentially predict the odds of major depression and bipolar disorder. J Affect Disord 159:23–30PubMedPubMedCentralGoogle Scholar
  16. 16.
    Nunes SO, Piccoli de Melo LG, Pizzo de Castro MR, Barbosa DS, Vargas HO, Berk M, Maes M (2015) Atherogenic index of plasma and atherogenic coefficient are increased in major depression and bipolar disorder, especially when comorbid with tobacco use disorder. J Affect Disord 172:55–62PubMedPubMedCentralGoogle Scholar
  17. 17.
    Moreira EG, Correia DG, Bonifácio KL, Moraes JB, Cavicchioli FL, Nunes CS, Nunes SOV, Vargas HO et al (2017) Lowered PON1 activities are strongly associated with depression and bipolar disorder, recurrence of (hypo)mania and depression, increased disability and lowered quality of life. World J Biol Psychiatry 30:1–13Google Scholar
  18. 18.
    Peet M, Murphy B, Shay J, Horrobin D (1998) Depletion of omega-3 fatty acid levels in red blood cell membranes of depressive patients. Biol Psychiatry 43(5):315–319PubMedPubMedCentralGoogle Scholar
  19. 19.
    Maes M, Smith R, Christophe A, Cosyns P, Desnyder R, Meltzer H (1996) Fatty acid composition in major depression: decreased omega 3 fractions in cholesteryl esters and increased C20: 4 omega 6/C20:5 omega 3 ratio in cholesteryl esters and phospholipids. J Affect Disord 38(1):35–46PubMedPubMedCentralGoogle Scholar
  20. 20.
    Maes M, Christophe A, Delanghe J, Altamura C, Neels H, Meltzer HY (1999) Lowered omega3 polyunsaturated fatty acids in serum phospholipids and cholesteryl esters of depressed patients. Psychiatry Res 85(3):275–291Google Scholar
  21. 21.
    Bilici M, Efe H, Köroğlu MA, Uydu HA, Bekaroğlu M, Değer O (2001) Antioxidative enzyme activities and lipid peroxidation in major depression: alterations by antidepressant treatments. J Affect Disord 64(1):43–51Google Scholar
  22. 22.
    Maes M, Mihaylova I, Leunis JC (2007) Increased serum IgM antibodies directed against phosphatidyl inositol (Pi) in chronic fatigue syndrome (CFS) and major depression: evidence that an IgM-mediated immune response against Pi is one factor underpinning the comorbidity between both CFS and depression. Neuro Endocrinol Lett 28(6):861–867PubMedPubMedCentralGoogle Scholar
  23. 23.
    Maes M, Mihaylova I, Kubera M, Uytterhoeven M, Vrydags N, Bosmans E (2010) Increased plasma peroxides and serum oxidized low density lipoprotein antibodies in major depression: markers that further explain the higher incidence of neurodegeneration and coronary artery disease. J Affect Disord 125(1–3):287–294Google Scholar
  24. 24.
    Maes M, Mihaylova I, Kubera M, Leunis JC, Geffard M (2011) IgM-mediated autoimmune responses directed against multiple neoepitopes in depression: new pathways that underpin the inflammatory and neuroprogressive pathophysiology. J Affect Disord 135(1–3):414–418Google Scholar
  25. 25.
    Maes M, Kubera M, Mihaylova I, Geffard M, Galecki P, Leunis JC, Berk M (2013) Increased autoimmune responses against auto-epitopes modified by oxidative and nitrosative damage in depression: implications for the pathways to chronic depression and neuroprogression. J Affect Disord 149(1–3):23–29Google Scholar
  26. 26.
    Khanzode SD, Dakhale GN, Khanzode SS, Saoji A, Palasodkar R (2003) Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors. Redox Rep 8(6):365–370Google Scholar
  27. 27.
    Ozcan ME, Gulec M, Ozerol E, Polat R, Akyol O (2004) Antioxidant enzyme activities and oxidative stress in affective disorders. Int Clin Psychopharmacol 19(2):89–95Google Scholar
  28. 28.
    Sarandol A, Sarandol E, Eker SS, Erdinc S, Vatansever E, Kirli S (2007) Major depressive disorder is accompanied with oxidative stress: short-term antidepressant treatment does not alter oxidative-antioxidative systems. Hum Psychopharmacol 22(2):67–73Google Scholar
  29. 29.
    Maes M, Kubera M, Leunis JC, Berk M, Geffard M, Bosmans E (2013) In depression, bacterial translocation may drive inflammatory responses, oxidative and nitrosative stress (O&NS), and autoimmune responses directed against O&NS-damaged neoepitopes. Acta Psychiatr Scand 127(5):344–354Google Scholar
  30. 30.
    Ranjekar PK, Hinge A, Hegde MV, Ghate M, Kale A, Sitasawad S, Wagh UV, Debsikdar VB et al (2003) Decreased antioxidant enzymes and membrane essential polyunsaturated fatty acids in schizophrenic and bipolar mood disorder patients. Psychiatry Res 121(2):109–122Google Scholar
  31. 31.
    Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Jr CV, da Silva Vargas R, Kapczinski F, Portela LV et al (2007) Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 421(1):33–36PubMedPubMedCentralGoogle Scholar
  32. 32.
    Kunz M, Gama CS, Andreazza AC, Salvador M, Ceresér KM, Gomes FA, Belmonte-de-Abreu PS, Berk M et al (2008) Elevated serum superoxide dismutase and thiobarbituric acid reactive substances in different phases of bipolar disorder and in schizophrenia. Prog Neuro-Psychopharmacol Biol Psychiatry 32(7):1677–1681Google Scholar
  33. 33.
    Bengesser SA, Lackner N, Birner A, Fellendorf FT, Platzer M, Mitteregger A, Unterweger R, Reininghaus B et al (2015) Peripheral markers of oxidative stress and antioxidative defense in euthymia of bipolar disorder—gender and obesity effects. J Affect Disord 172:367–374PubMedPubMedCentralGoogle Scholar
  34. 34.
    Chowdhury MI, Hasan M, Islam MS, Sarwar MS, Amin MN, Uddin SM, Rahaman MZ, Banik S et al (2017) Elevated serum MDA and depleted non-enzymatic antioxidants, macro-minerals and trace elements are associated with bipolar disorder. J Trace Elem Med Biol 39:162–168PubMedPubMedCentralGoogle Scholar
  35. 35.
    Liu T, Zhong S, Liao X, Chen J, He T, Lai S, Jia Y (2015) A meta-analysis of oxidative stress markers in depression. PLoS One 10(10):e0138904PubMedPubMedCentralGoogle Scholar
  36. 36.
    Mazereeuw G, Herrmann N, Andreazza AC, Khan MM, Lanctôt KL (2015) A meta-analysis of lipid peroxidation markers in major depression. Neuropsychiatr Dis Treat 11:2479–2491PubMedPubMedCentralGoogle Scholar
  37. 37.
    Andreazza AC, Kauer-Sant'anna M, Frey BN, Bond DJ, Kapczinski F, Young LT, Yatham LN (2008) Oxidative stress markers in bipolar disorder: a meta-analysis. J Affect Disord 111(2–3):135–144PubMedPubMedCentralGoogle Scholar
  38. 38.
    Brown NC, Andreazza AC, Young LT (2014) An updated meta-analysis of oxidative stress markers in bipolar disorder. Psychiatry Res 218(1–2):61–68PubMedPubMedCentralGoogle Scholar
  39. 39.
    Maes M, Meltzer HY, Bosmans E, Bergmans R, Vandoolaeghe E, Ranjan R, Desnyder R (1995) Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord 34(4):301–309PubMedPubMedCentralGoogle Scholar
  40. 40.
    Gomes C, Martinho FC, Barbosa DS, Antunes LS, Póvoa HCC, Baltus THL, Morelli NR, Vargas HO et al (2017) Increased root canal endotoxin levels are associated with chronic apical periodontitis, increased oxidative and nitrosative stress, major depression, severity of depression, and a lowered quality of life. Mol Neurobiol.  https://doi.org/10.1007/s12035-017-0545-z
  41. 41.
    Roomruangwong C, Barbosa DS, Matsumoto AK, Nogueira AS, Kanchanatawan B, Sirivichayakul S, Carvalho AF, Duleu S et al (2017) Activated neuro-oxidative and neuro-nitrosative pathways at the end of term are associated with inflammation and physio-somatic and depression symptoms, while predicting outcome characteristics in mother and baby. J Affect Disord 223:49–58Google Scholar
  42. 42.
    Marsche G, Frank S, Hrzenjak A, Holzer M, Dirnberger S, Wadsack C, Scharnagl H, Stojakovic T et al (2009) Plasma-advanced oxidation protein products are potent high-density lipoprotein receptor antagonists in vivo. Circ Res 104(6):750–757PubMedPubMedCentralGoogle Scholar
  43. 43.
    Gałecki P, Gałecka E, Maes M, Chamielec M, Orzechowska A, Bobińska K, Lewiński A, Szemraj J (2012) The expression of genes encoding for COX-2, MPO, iNOS, and sPLA2-IIA in patients with recurrent depressive disorder. J Affect Disord 138(3):360–366PubMedPubMedCentralGoogle Scholar
  44. 44.
    Morris G, Berk M, Klein H, Walder K, Galecki P, Maes M (2017) Nitrosative stress, hypernitrosylation, and autoimmune responses to nitrosylated proteins: new pathways in neuroprogressive disorders including depression and chronic fatigue syndrome. Mol Neurobiol 54(6):4271–4291PubMedPubMedCentralGoogle Scholar
  45. 45.
    Savas HA, Gergerlioglu HS, Armutcu F, Herken H, Yilmaz HR, Kocoglu E, Selek S, Tutkun H et al (2006) Elevated serum nitric oxide and superoxide dismutase in euthymic bipolar patients: impact of past episodes. World J Biol Psychiatry 7(1):51–55Google Scholar
  46. 46.
    Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P et al (2009) The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 24(1):27–53Google Scholar
  47. 47.
    Del-Ben CM, Vilela JAA, Crippa JAS, Hallak JEC, Labate CM et al (2001) Confiabilidade da "Entrevista Clínica Estruturada para o DSM-IV - Versão Clínica" traduzida para o português. Rev Bras Psiquiatr 23:156–159Google Scholar
  48. 48.
    American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th ed., Text Revision edn. Author, Washington, DCGoogle Scholar
  49. 49.
    Moreno RA, Moreno DH (1998) Escalas de depressao de Montgomery & Asberg (MADRS) e de Hamilton (HAM-D) / Hamilton and Montgomery & Asberg depression rating scales. Rev Psiquiatr Clín 25:262–272Google Scholar
  50. 50.
    Vilela JA, Crippa JA, Del-Ben CM, Loureiro SR (2005) Reliability and validity of a Portuguese version of the Young Mania Rating Scale. Braz J Med Biol Res 38(9):1429–1439Google Scholar
  51. 51.
    WHO ASSIST Working Group (2002) The Alcohol, Smoking and Substance Involvement Screening Test (ASSIST): development, reliability and feasibility. Addiction 97:1183–1194Google Scholar
  52. 52.
    Henrique IFS, De Micheli D, Lacerda RB, Lacerda LA, Formigoni MLOS (2004) Validação da versão brasileira do teste de triagem do envolvimento com álcool, cigarro e outras substâncias (ASSIST). Rev Assoc Med Bras 5:199–206Google Scholar
  53. 53.
    Heatherton TF, Kozlowski LT, Frecker RC, Fagerström KO (1991) The Fagerström test for nicotine dependence: a revision of the Fagerström tolerance questionnaire. Br J Addict 86(9):1119–1127PubMedPubMedCentralGoogle Scholar
  54. 54.
    de Meneses-Gaya C, Zuardi AW, de Azevedo Marques JM, Souza RM, Loureiro SR, Crippa JA (2009) Psychometric qualities of the Brazilian versions of the Fagerström Test for Nicotine Dependence and the Heaviness of Smoking Index. Nicotine Tob Res 11(10):1160–1165PubMedPubMedCentralGoogle Scholar
  55. 55.
    Alberti KG, Zimmet P, Shaw J (2006) Metabolic syndrome—a new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med 23(5):469–480PubMedPubMedCentralGoogle Scholar
  56. 56.
    Marklund S, Marklund G (1974) Involvement of the superoxide dismutase anion radical in the autoxidation of pyrogallol and a convenient assay for superoxide dismutase. Eur J Biochem 47:469–471PubMedPubMedCentralGoogle Scholar
  57. 57.
    Gonzalez Flecha B, Llesuy S, Boveris A (1991) Hydroperoxide-initiated chemiluminescence: An assay for oxidative stress in biopsies of heart, liver, and muscle. Free Radic Biol Med 10:93–100PubMedPubMedCentralGoogle Scholar
  58. 58.
    Panis C, Herrera ACSA, Victorino VJ, Campos FC, Freitas LF, De Rossi T, Colado Simao AN, Cecchini AL et al (2012) Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy. Breast Cancer Res Treat 133:89–97PubMedPubMedCentralGoogle Scholar
  59. 59.
    Navarro-Gonzalvez JA, Garcia-Benayas C, Arenas J (1998) Semiautomated measurement of nitrate in biological fluids. Clin Chem 44:679–681PubMedPubMedCentralGoogle Scholar
  60. 60.
    Bastos AS, Loureiro AP, de Oliveira TF, Corbi SC, Caminaga RM, Junior CR, Orrico SR (2012) Quantitation of malondialdehyde in gingival crevicular fluid by a high-performance liquid chromatography-based method. Anal Biochem 423:141–146Google Scholar
  61. 61.
    Hanasand M, Omdal R, Norheim KB, Gransson LG, Brede C, Jonsson G (2012) Improved detection of advanced oxidation protein products in plasma. Clin Chim Acta 413:901–906Google Scholar
  62. 62.
    Hayyan M, Hashim MA, AlNashef IM (2016) Superoxide ion: generation and chemical implications. Chem Rev 116(5):3029–3085PubMedGoogle Scholar
  63. 63.
    Girotti AW (1998) Lipid hydroperoxide generation, turnover, and effector action in biological systems. J Lipid Res 39(8):1529–1542Google Scholar
  64. 64.
    Pacher P, Beckman JS, Liaudet L (2007) Nitric oxide and peroxynitrite in health and disease. Physiol Rev 87(1):315–424PubMedPubMedCentralGoogle Scholar
  65. 65.
    Benjamini Y, Hochberg Y (1995) Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B Methodol 57:289–300Google Scholar
  66. 66.
    Fukai T, Ushio-Fukai M (2011) Superoxide dismutases: role in redox signaling, vascular function, and diseases. Antioxid Redox Signal 15(6):1583–1606PubMedPubMedCentralGoogle Scholar
  67. 67.
    McCord JM, Edeas MA (2005) SOD, oxidative stress and human pathologies: a brief history and a future vision. Biomed Pharmacother 59(4):139–142PubMedPubMedCentralGoogle Scholar
  68. 68.
    Harris ED (1992) Copper as a cofactor and regulator of copper, zinc superoxide dismutase. J Nutr 122(3 Suppl):636–640PubMedPubMedCentralGoogle Scholar
  69. 69.
    Terrazzano G, Rubino V, Damiano S, Sasso A, Petrozziello T, Ucci V, Palatucci AT, Giovazzino A et al (2014) Ruggiero G (2014) T cell activation induces CuZn superoxide dismutase (SOD)-1 intracellular re-localization, production and secretion. Biochim Biophys Acta 1843(2):265–274Google Scholar
  70. 70.
    Roomruangwong C, Barbosa DS, de Farias CC, Matsumoto AK, Baltus THL, Morelli NR, Kanchanatawan B, Duleu S et al (2017) Natural regulatory IgM-mediated autoimmune responses directed against malondialdehyde regulate oxidative and nitrosative pathways and coupled with IgM responses to nitroso-adducts attenuate depressive and physiosomatic symptoms at the end of term pregnancy. Psychiatry Clin Neurosci.  https://doi.org/10.1111/pcn.12625
  71. 71.
    Kudlow P, Cha DS, Carvalho AF, McIntyre RS (2016) Nitric oxide and major depressive disorder: pathophysiology and treatment implications. Curr Mol Med 16(2):206–215Google Scholar
  72. 72.
    Morris G, Walder K, Carvalho AF, Tye SJ, Lucas K, Berk M, Maes M (2018) The role of hypernitrosylation in the pathogenesis and pathophysiology of neuroprogressive diseases. Neurosci Biobehav Rev 84:453–469Google Scholar
  73. 73.
    Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21(12):1696–1709PubMedPubMedCentralGoogle Scholar
  74. 74.
    Siwek M, Sowa-Kućma M, Styczeń K, Misztak P, Nowak RJ, Szewczyk B, Dudek D, Rybakowski JK et al (2017) Associations of serum cytokine receptor levels with melancholia, staging of illness, depressive and manic phases, and severity of depression in bipolar disorder. Mol Neurobiol 54(8):5883–5893Google Scholar
  75. 75.
    Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A (2003) Protein carbonylation in human diseases. Trends Mol Med 9(4):169–176Google Scholar
  76. 76.
    Gryszczyńska B, Formanowicz D, Budzyń M, Wanic-Kossowska M, Pawliczak E, Formanowicz P, Majewski W, Strzyżewski KW et al (2017) Advanced oxidation protein products and carbonylated proteins as biomarkers of oxidative stress in selected atherosclerosis-mediated diseases. Biomed Res Int 2017:4975264PubMedPubMedCentralGoogle Scholar
  77. 77.
    Grimsrud PA, Xie H, Griffin TJ, Bernlohr DA (2008) Oxidative stress and covalent modification of protein with bioactive aldehydes. J Biol Chem 283(32):21837–21841PubMedPubMedCentralGoogle Scholar
  78. 78.
    Lu YA, Lee SY, Chen SL, Chen SH, Chu CH, Tzeng NS, Huang SY, Kuo PH et al (2012) Gene-temperament interactions might distinguish between bipolar I and bipolar II disorders: a cross-sectional survey of Han Chinese in Taiwan. J Clin Psychiatry 73(3):339–345PubMedPubMedCentralGoogle Scholar
  79. 79.
    Caseras X, Lawrence NS, Murphy K, Wise RG, Phillips ML (2013) Ventral striatum activity in response to reward: differences between bipolar I and II disorders. Am J Psychiatry 170(5):533–541PubMedPubMedCentralGoogle Scholar
  80. 80.
    Katalinic V, Modun D, Music I, Boban M (2005) Gender differences in antioxidant capacity of rat tissues determined by 2,2′-azinobis (3-ethylbenzothiazoline 6-sulfonate; ABTS) and ferric reducing antioxidant power (FRAP) assays. Comp Biochem Physiol Part C Toxicol Pharmacol 140(1):47–52Google Scholar
  81. 81.
    Lobo V, Patil A, Phatak A, Chandra N (2010) Free radicals, antioxidants and functional foods: Impact on human health. Pharmacogn Rev 4(8):118–126PubMedPubMedCentralGoogle Scholar
  82. 82.
    Moylan S, Eyre HA, Maes M, Baune BT, Jacka FN, Berk M (2013) Exercising the worry away: how inflammation, oxidative and nitrogen stress mediates the beneficial effect of physical activity on anxiety disorder symptoms and behaviours. Neurosci Biobehav Rev 37(4):573–584PubMedPubMedCentralGoogle Scholar
  83. 83.
    van der Vaart H, Postma DS, Timens W, ten Hacken NH (2004) Acute effects of cigarette smoke on inflammation and oxidative stress: a review. Thorax 59(8):713–721PubMedPubMedCentralGoogle Scholar
  84. 84.
    Donohue JF (2006) Ageing, smoking and oxidative stress. Thorax 61(6):461–462PubMedPubMedCentralGoogle Scholar
  85. 85.
    Nunes SO, Vargas HO, Prado E, Barbosa DS, de Melo LP, Moylan S, Dodd S, Berk M (2013) The shared role of oxidative stress and inflammation in major depressive disorder and nicotine dependence. Neurosci Biobehav Rev 37(8):1336–1345Google Scholar
  86. 86.
    Andriollo-Sanchez M, Hininger-Favier I, Meunier N, Venneria E, O'Connor JM, Maiani G, Coudray C, Roussel AM (2005) Age-related oxidative stress and antioxidant parameters in middle-aged and older European subjects: the ZENITH study. Eur J Clin Nutr 59(Suppl 2):S58–S62Google Scholar
  87. 87.
    Romano AD, Serviddio G, de Matthaeis A, Bellanti F, Vendemiale G (2010) Oxidative stress and aging. J Nephrol 23(Suppl 15):S29–S36PubMedPubMedCentralGoogle Scholar
  88. 88.
    Zachar P, Stoyanov DS, Aragona M, Jablensky A (eds) (2014) Alternative perspectives on psychiatric validation: DSM, ICD, RDoC, and Beyond. OUP, OxfordGoogle Scholar
  89. 89.
    Maes M, Schotte C, Maes L, Cosyns P (1990) Clinical subtypes of unipolar depression: Part II. Quantitative and qualitative clinical differences between the vital and nonvital depression groups. Psychiatry Res 34(1):43–57PubMedPubMedCentralGoogle Scholar
  90. 90.
    Maes M, Cosyns P, Maes L, D'Hondt P, Schotte C (1990) Clinical subtypes of unipolar depression: Part I. A validation of the vital and nonvital clusters. Psychiatry Res 34(1):29–41Google Scholar
  91. 91.
    Kanchanatawan B, Sriswasdi S, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Kubera M, Maes M (2018) Deficit schizophrenia is a discrete diagnostic category defined by neuro-immune and neurocognitive features: results of supervised machine learning. Metab Brain Dis.  https://doi.org/10.1007/s11011-018-0208-4
  92. 92.
    Loscalzo J, Kohane I, Barabasi AL (2007) Human disease classification in the postgenomic era: a complex systems approach to human pathobiology. Mol Syst Biol 3:124PubMedPubMedCentralGoogle Scholar
  93. 93.
    Maes M, Nowak G, Caso JR, Leza JC, Song C, Kubera M, Klein H, Galecki P et al (2016) Toward omics-based, systems biomedicine, and path and drug discovery methodologies for depression-inflammation research. Mol Neurobiol 53(5):2927–2935Google Scholar
  94. 94.
    Kendler KS, Parnas J (eds) (2015) Philosophical issues in psychiatry: explanation, phenomenology, and nosology. JHU Press, BaltimoreGoogle Scholar
  95. 95.
    Maes M, Galecki P, Verkerk R, Rief W (2011) Somatization, but not depression, is characterized by disorders in the tryptophan catabolite (TRYCAT) pathway, indicating increased indoleamine 2,3-dioxygenase and lowered kynurenine aminotransferase activity. Neuro Endocrinol Lett 32(3):264–273Google Scholar
  96. 96.
    Maes M, Rief W (2012) Diagnostic classifications in depression and somatization should include biomarkers, such as disorders in the tryptophan catabolite (TRYCAT) pathway. Psychiatry Res 196(2–3):243–249Google Scholar
  97. 97.
    Maes M, Maes L, Schotte C, Vandewoude M, Martin M, D'Hondt P, Blockx P, Scharpé S et al (1990) Clinical subtypes of unipolar depression: Part III. Quantitative differences in various biological markers between the cluster-analytically generated nonvital and vital depression classes. Psychiatry Res 34(1):59–75PubMedPubMedCentralGoogle Scholar
  98. 98.
    Kanchanatawan B, Thika S, Sirivichayakul S, Carvalho AF, Geffard M, Maes M (2018) In Schizophrenia, depression, anxiety, and physiosomatic symptoms are strongly related to psychotic symptoms and excitation, impairments in episodic memory, and increased production of neurotoxic tryptophan catabolites: a multivariate and machine learning study. Neurotox Res.  https://doi.org/10.1007/s12640-018-9868-4

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Michael Maes
    • 1
    • 2
    • 3
    • 4
    Email author
  • Kamila Landucci Bonifacio
    • 1
  • Nayara Rampazzo Morelli
    • 1
  • Heber Odebrecht Vargas
    • 1
  • Décio Sabbatini Barbosa
    • 1
  • André F. Carvalho
    • 5
    • 6
  • Sandra Odebrecht Vargas Nunes
    • 1
  1. 1.Health Sciences Graduation Program, Health Sciences CenterState University of LondrinaParanáBrazil
  2. 2.Department of Psychiatry, Faculty of MedicineChulalongkorn UniversityBangkokThailand
  3. 3.Department of PsychiatryMedical University of PlovdivPlovdivBulgaria
  4. 4.IMPACT Strategic Research Centre, School of MedicineDeakin UniversityVicAustralia
  5. 5.Department of PsychiatryUniversity of TorontoTorontoCanada
  6. 6.Centre for Addiction & Mental HealthTorontoCanada

Personalised recommendations